What is Illumina?
Genomics sequencing platforms company with $4.34B 2025 revenue scale and public-market buying capacity.
- Category
- Genomics sequencing platforms
- Headquarters
- San Diego, CA
- Founded
- 1998
- Employees
- 9,000+
- Total funding
- Public company; no VC funding
- Status
- Nasdaq: ILMN; Public company
What is Illumina?
Illumina is a public genomics sequencing platforms company headquartered in San Diego, CA. Illumina reported fiscal 2025 revenue of $4.34 billion, flat compared with 2024, with ex-China revenue of $4.10 billion.
Illumina operates in genomics sequencing platforms with a portfolio that includes NovaSeq X, NextSeq, MiSeq, Library prep and sequencing consumables. Illumina reported fiscal 2025 revenue of $4.34 billion, flat compared with 2024, with ex-China revenue of $4.10 billion. The company employs about 9,000+ and trades as Nasdaq: ILMN, so its buying motion looks like a regulated enterprise account rather than a startup account.
Its scale comes from clinically regulated products, payer or provider relationships, recurring consumables or services, intellectual property, manufacturing quality systems, and commercial access. Customers and partners evaluate Illumina through clinical outcomes, regulatory execution, supply reliability, reimbursement, data security, and total cost of care.
For sellers, Illumina is a multi-stakeholder account. Procurement, finance, clinical, quality, regulatory, legal, privacy, security, IT, operations, commercial, and business-unit leaders can all influence vendor approval. Strong pitches connect directly to patient impact, compliance, revenue capture, operating leverage, risk reduction, uptime, or measurable productivity.
What does Illumina offer?
Illumina offers products and services across NovaSeq X, NextSeq, MiSeq, Library prep and sequencing consumables and related healthcare workflows.
- NovaSeq X· Sequencing systems
- NextSeq· Sequencing systems
- MiSeq· Sequencing systems
- Library prep and sequencing consumables· Consumables
- Illumina Connected Software· Informatics
- Clinical genomics workflows· Clinical
How does Illumina make money?
Illumina earns revenue through regulated healthcare products, services, recurring consumables, software-enabled workflows, market access, and enterprise contracts.
Illumina earns revenue from products and services sold to healthcare systems, clinicians, payers, labs, pharmacies, governments, distributors, life-science customers, or patients depending on the business line. In 2025, that model produced $4.34B 2025 of reported revenue scale. Growth is tied to product demand, procedure or test volumes, prescription access, installed-base utilization, new indications, geographic reach, and disciplined pricing.
Pricing is not a public self-serve tier. It is negotiated by therapy, device, test, payer coverage, account type, contract term, service level, GPO or distributor structure, reimbursement, and geography. The practical tiers are enterprise account segmentation, clinical evidence review, value-analysis committee approval, data/security review, legal terms, and renewal or tender economics.
Vendors should expect mature procurement and high evidence requirements. Budgets open when a proposal helps Illumina improve launch execution, manufacturing resilience, clinical operations, data quality, regulatory readiness, patient access, field productivity, cybersecurity, or cost-to-serve.
Who leads Illumina?
Illumina is led by Jacob Thaysen, with finance, R&D, commercial, technology, medical, operations, and business-unit leaders shaping major enterprise decisions.
- Jacob ThaysenChief Executive OfficerCEO since 2023Leads Illumina's sequencing-platform reset after the GRAIL divestiture.
- Ankur DhingraChief Financial OfficerCFO since 2024Oversees finance, margin improvement, and investor planning.
- Steve BarnardChief Technology OfficerCTO in 2026Guides sequencing technology, informatics, and platform roadmaps.
- Susan TousiChief Commercial OfficerCommercial leader in 2026Leads commercial execution across clinical and research markets.
How do you contact Illumina's leadership?
Illumina publishes ir@illumina.com and official investor-relations contact routes, but it does not publish verified personal executive emails for the leaders listed here. Use the official investor, media, supplier, compliance, or contact form routes rather than guessed personal addresses.
ir@illumina.com and official investor-relations contact routes; personal executive email format not verifiedHow much funding has Illumina raised?
Illumina is a mature public company, not a venture-backed startup. It trades as Nasdaq: ILMN and funds growth through operating cash flow, public-market access, debt markets, partnerships, and acquisition capacity.
Illumina's capital history is a public-company story rather than a disclosed venture-round history. The relevant funding events are founding, public listing, major acquisitions or divestitures, retained earnings, debt capacity, R&D reinvestment, manufacturing investment, and shareholder capital allocation.
As of June 2026, the current capital lens is Nasdaq: ILMN, $4.34B 2025 of 2025 revenue scale, and management's ability to fund launches, facilities, technology, clinical programs, supply chain, compliance, and business development. That is materially different from a startup where the next round controls hiring and tool budgets.
Seller signal: Illumina has enterprise buying power, but budget access is tied to risk, ROI, auditability, executive sponsorship, and integration fit. Procurement is more likely to approve projects that reduce operational friction, protect regulated workflows, improve patient or customer outcomes, or support a named business priority.
How did Illumina get here?
Illumina grew through founding, product expansion, public-market scale, strategic portfolio moves, and regulated healthcare execution.
- 1998Illumina foundedThe company begins commercializing array and sequencing technologies.
- 2000IPOIllumina becomes public.
- 2007Solexa acquisitionIllumina acquires Solexa and accelerates next-generation sequencing.
- 2023Jacob Thaysen becomes CEOIllumina enters a leadership reset.
- 2024GRAIL divestiture completedIllumina refocuses on core sequencing.
- 2025$4.34B revenueIllumina reports fiscal 2025 revenue of $4.34 billion.
Who are Illumina's competitors?
Illumina competes with large healthcare, pharma, diagnostics, life-science, and medtech companies that overlap in products, customers, procurement budgets, and clinical workflows.
- Thermo Fisher ScientificCompetes in sequencing instruments, reagents, sample prep, and clinical genomics workflows.
- Pacific BiosciencesCompetes in long-read sequencing and genomics research platforms.
- Oxford NanoporeCompetes in long-read, portable, and real-time sequencing.
- Element BiosciencesCompetes in benchtop sequencing cost and workflow.
- MGI TechCompetes in sequencing platforms and consumables globally.
- QIAGENCompetes in sample prep, molecular diagnostics, and sequencing-adjacent workflows.
Illumina — frequently asked questions
